<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85752">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02014350</url>
  </required_header>
  <id_info>
    <org_study_id>RI2013</org_study_id>
    <nct_id>NCT02014350</nct_id>
  </id_info>
  <brief_title>Outcomes Following Delta Xtend Reverse Shoulder System</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rothman Institute Orthopaedics</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rothman Institute Orthopaedics</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To collect medium to long-term survivorship implant outcomes on the DePuy Delta Xtend
      Reverse Shoulder Stystem.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Implant Survivorship</measure>
    <time_frame>10 years post-operative</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <condition>Reverse Total Shoulder Arthroplasty</condition>
  <arm_group>
    <arm_group_label>DePuy Delta Xtend RTSA</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DePuy Delta Xtend Reverse TSA</intervention_name>
    <arm_group_label>DePuy Delta Xtend RTSA</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients who were implanted with the DePuy Delta Xtend Reverse Total Shoulder Arthoplasty
        between 2008-2012
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients whom were implanted with the DePuy Delta Xtend Reverse Total Shoulder System in
        the time frame indicated.  Patients must be willing to sign the consent form and complete
        all follow-up visits.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Rothman Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 17, 2013</lastchanged_date>
  <firstreceived_date>December 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
